EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Hospital Adoption and Pricing for Oncology Biosimilars

James C Robinson, Ari D Kosorukov, Christopher M Whaley

JAMA · 2026

DOI: 10.1001/jama.2026.1777 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA, 2026. Verfasst von James C Robinson und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Berkeley. Hauptthemen laut MEDLINE: Antineoplastic Agents, Biosimilar Pharmaceuticals, Drug Costs, Hospital Charges. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Many physician-administered oncology biologics are losing patent protection in the coming years and will face competition from biosimilars. Hospitals and insurers share a mutual interest in developing payment methods that share the potential savings from adopting these less costly agents.

Objective

To test whether hospitals paid lower acquisition prices and earned higher markup margins for physician-administered oncology biosimilars; whether insurers reduced the reimbursement prices they paid to hospitals, thereby sharing in the savings from lower manufacturer prices; and whether reductions in acquisition prices and increases in hospital margins were associated with accelerated adoption of biosimilars. Design, Setting, and Participants Observational study using 2020-2024 data for patients covered by Blue Cross Blue Shield health insurance, linked to information on drug acquisition prices paid by hospitals to manufacturers; drug reimbursement prices paid by insurers to hospitals; hospital eligibility for federal 340B price discounts; and other hospital, patient, and market characteristics. Exposures Biologics and biosimilars acquired by hospitals from manufacturers at one price and reimbursed by private insurers at a higher price. Main Outcomes and Measures Acquisition prices paid by hospitals to manufacturers, reimbursement prices paid by insurers to hospitals, hospital drug price markup margin, hospital adoption of biosimilars.

Results

Between 2020 and 2024 (66 139 patients who received oncology biologics and biosimilars in 1541 hospitals), acquisition prices paid by hospitals to drug manufacturers declined by 60%, 72%, and 63% for the biosimilars of bevacizumab, trastuzumab, and rituximab, respectively. The reimbursement prices paid by insurers to hospitals declined more slowly, at 32%, 36%, and 34%, allowing an increase in hospital markup margins. In multivariable regression analyses, each additional dollar of acquisition price was associated with $2.72 in higher hospital reimbursement for bevacizumab (95% CI, $0.51-$4.93), $1.82 for trastuzumab (95% CI, $1.27-2.38), and $2.32 for rituximab (95% CI, $1.56-$3.09). Increases in hospital markup margins were associated with increased adoption of biosimilars, rising from a 32%, 37%, and 18% share of bevacizumab, trastuzumab, and rituximab use in 2020 to 93%, 87%, and 84% by 2024. Conclusions and Relevance Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBiosimilar PharmaceuticalsDrug CostsHospital ChargesHospital CostsInsurance, Health, ReimbursementNeoplasmsAdultFemaleHumansMaleMiddle AgedBevacizumabBlue Cross Blue Shield Insurance PlansEconomic CompetitionRituximabTrastuzumabUnited States

Substanzen

Antineoplastic AgentsBevacizumabBiosimilar PharmaceuticalsRituximabTrastuzumab

Autor:innen und Institutionen

  • University of California, Berkeley.
  • Brown University, Providence, Rhode Island.

Zitieren

APA

Robinson, J. C., Kosorukov, A. D., & Whaley, C. M. (2026). Hospital Adoption and Pricing for Oncology Biosimilars. JAMA. https://doi.org/10.1001/jama.2026.1777

Vancouver

Robinson JC, Kosorukov AD, Whaley CM. Hospital Adoption and Pricing for Oncology Biosimilars. JAMA. 2026. doi:10.1001/jama.2026.1777

BibTeX
@article{Robinson2026,
  author = {Robinson, James C and Kosorukov, Ari D and Whaley, Christopher M},
  title = {Hospital Adoption and Pricing for Oncology Biosimilars},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.1777}
}
Kostenlos starten →